Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
The win Restorbio is claiming in a mid-stage study is by no means clear-cut.
Mid-stage data for Tocagen and Restorbio are approaching.
Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.